A laboratory designed methodology utilizing low dose multi-drug chemotherapy. The low dose regimen minimizes toxicity and maximizes synergy tartgeting multiple pathways simultaneously. We have doubled the survival in pancreatic cancer using this methodology. We have successfully applied this to many other cancers that have failed standard regimens.http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35265